SCHEMBL20028140

SCHEMBL20028140

COC(=O)c1cc(C)nn1-c1ccc(CNC(=O)c2ccccc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.64
ALDH1A1 P00352 3/20 0.55
HPGD P15428 3/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
RECQL P46063 1/20 0.51
KMT2A Q03164 2/20 0.51
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
DHODH Q02127 2/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22897209 0.90 MAPT (0.68) MAPTALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL20028137 0.86 TP53 (0.49) MAPTALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL20028059 0.86 MAPT (0.57) MAPTALDH1A1HPGDKMT2AGAA
SCHEMBL20028202 0.85 MAPT (0.55) MAPTALDH1A1HPGDKMT2AGAA
SCHEMBL20028525 0.85 MAPT (0.55) MAPTALDH1A1HPGDKMT2AGAA
SCHEMBL22896939 0.84 MAPT (0.55) MAPTALDH1A1HPGDL3MBTL1SMN1; SMN2
SCHEMBL22896512 0.84 MAPT (0.55) MAPTALDH1A1HPGDKMT2AL3MBTL1
SCHEMBL20027618 0.82 MAPT (0.52) MAPTALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL20027869 0.81 MAPT (0.52) MAPTALDH1A1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL20028524 0.81 KMT2A (0.60) MAPTALDH1A1HPGDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885ALDH1A1 4193/4885HPGD 2346/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 MAPT 330/4885ALDH1A1 4421/4885HPGD 2414/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 MAPT 562/4885ALDH1A1 4193/4885HPGD 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.